Anatomy-based breast implant planning evidence supports a simple but important correction to volume-first thinking: a breast implant is not a stand-alone number. Its volume, width and projection are expressed through a particular chest wall, breast base, skin envelope, tissue coverage, posture and set of patient goals. The same nominal implant can therefore create different proportions, different palpable or visible contours and different trade-offs in two otherwise similar patients.
This anatomy-based breast implant planning evidence review synthesises evidence for primary cosmetic breast augmentation. It does not treat reconstruction, revision surgery, tuberous breasts, Poland syndrome, marked ptosis or augmentation-mastopexy as interchangeable populations. Those situations may require additional measurements or a different operation. The aim is not to produce a universal sizing formula. It is to explain how a consultation can turn anatomy and preferences into a documented, proportionate plan while being honest about what the evidence cannot predict.
Why implant planning moved beyond volume
The history of breast implants helps explain the change. Early device discussions naturally focused on the material, filler and nominal volume: what could be inserted and how much space it occupied. As implants acquired different widths, profiles, shapes, gels, and pocket options, surgeons had to confront a practical problem: adding a known volume does not force a predictable three-dimensional result.
Perry and Frame’s historical review describes augmentation outcomes as dependent on several interacting features, including chest-wall symmetry, the frame and vectors of the myoskeleton, the shape and consistency of the breast, its position or ptosis, the compliance of the skin and fatty envelope, and the way volume is added. That is historical and surgical context, not a trial proving that one modern technique is superior. It does, however, explain why contemporary planning increasingly starts with the patient rather than a catalogue volume.
The influential TEPID system described by Tebbetts made this logic explicit. It used breast-parenchyma base width, skin stretch and the nipple- or areola-to-inframammary-fold distance under stretch to estimate how an implant would fill an individual envelope. Pinch thickness at the upper pole and fold was used to inform coverage and pocket decisions. The later “High Five” process retained a tissue-matching philosophy and added five critical decisions and measurements. These are clinical decision-support systems developed from case series, not randomised proof that one algorithm works for every body. Their lasting contribution is conceptual: the implant should fit the tissue instead of asking the tissue to carry an unsuitable device.
The systematic review by Adams and McKee found 33 published implant size-selection systems. Only four reported outcomes that could be compared with accepted literature values or industry standards. Tissue-based systems had the strongest methodological quality in that review, but the authors did not establish one validated formula. This is why the word “anatomy-based” should describe a disciplined process, not a promise that a measurement produces a guaranteed result.
For a related explanation of the dimensional history, see the research article on implant profile and projection evidence and the companion review of implant dimensions, base width and cc.
The six parts of a personalised planning framework
1. Chest width sets the surrounding frame
Chest width is not a crude proxy for body size. It describes the bony and soft-tissue frame on which the breast sits, including the contour of the rib cage, the medial space between breasts, the lateral boundary and the direction in which the chest wall slopes. A front-facing photograph can hide these relationships. One side may also have a different base, fold or chest-wall contour from the other.
The practical implication is that an implant’s footprint must be considered alongside its volume. A broad, lower-projecting implant distributes volume across more of the chest. A narrower, more projecting implant puts more of the change forward. If the device is wider than the tissues can comfortably support, the lateral contour, intermammary distance and fold may be affected. If it is too narrow for the patient’s desired breadth, a high volume may create projection without the fullness the patient imagined.
There is no single chest-width threshold that determines the correct implant. Chest width is an anchoring observation that must be combined with the natural breast base, existing tissue and desired proportions. It is also a reason not to transfer another person’s implant volume from a photograph to a new patient.
2. Breast base and landmarks describe the footprint
The breast base is the tissue footprint on the chest, not the same thing as an implant’s diameter. A clinical assessment may consider breast width and height, the inframammary fold, the nipple-to-fold distance, nipple position, breast spacing, lower-pole length and asymmetry. These landmarks describe where the breast begins and how much of the skin envelope is available to accommodate volume.
The 2020 prospective study by Charles-de-Sá and colleagues followed 74 women divided into groups by implant volume. It measured nipple-to-inframammary-fold distance, inter-nipple distance, sternal-notch-to-nipple distance, areola diameter and projection. The most prominent change was lower-pole expansion, and many measurements were stable between three and six months in that study. It was graded as level IV evidence by the journal, despite its prospective randomised grouping, so its measurements should be treated as useful observations rather than a universal prediction.
Bolletta, McGoldrick and Hall-Findlay analysed standardised breast measurements before and after aesthetic surgery, including a primary augmentation group. They reported that adding an implant expanded parts of the breast footprint and stretched the existing sternal-notch-to-nipple relationship. The study used one surgeon and included patients with complete one-year follow-up, which limits generalisability, but it reinforces a key point: volume changes landmarks and envelope geometry, not only cup appearance.
An anatomy-led consultation therefore asks where the proposed implant will sit in relation to the patient’s actual base and fold. It does not assume that a device with the right cc automatically has the right footprint.
3. Tissue coverage determines how implant geometry is expressed
Tissue coverage means the skin, subcutaneous tissue, breast parenchyma, fascia and, where relevant, muscle that separate the implant from the outside world. Coverage is not necessarily uniform. The upper pole may be thin while the lower or lateral pole has a different thickness. Pinch testing can inform the discussion, but it cannot map every tissue layer or predict how a patient’s tissue will age.
When coverage is limited, implant edges, folds or rippling may be easier to see or feel. A large or highly projecting device can place greater demand on the envelope. Over time, pressure and stretching may contribute to thinning, ptosis, lower-pole descent or malposition, although these outcomes are multifactorial and cannot be attributed to volume alone. Existing breast tissue, implant fill behaviour, pocket dimensions, smoking, weight change, pregnancy, ageing and surgical technique all matter.
Pocket selection is part of the same calculation. Subglandular, subfascial, subpectoral and dual-plane placements create different relationships between implant, muscle and breast tissue. A 2024 systematic review and meta-analysis comparing subfascial and subglandular augmentation reported some differences in outcomes but judged all included studies to be at high risk of bias and called for stronger randomised evidence. The responsible conclusion is not that one plane is universally best; it is that coverage, muscle movement, tissue quality and patient priorities should be discussed together.
The clinical literature also contains attempts to measure firmness or tissue quality. A 2017 level-III study of a breast durometer found reproducible measurements in a small series and described changes in firmness after subfascial augmentation. This is an interesting research direction, not a routine tool that can replace examination. In everyday planning, skin thickness, stretch, laxity, existing tissue and the position of the breast remain clinical judgements supported by measurements where useful.
4. Skin quality and stretch limit what volume can safely achieve
Skin quality is more than whether the skin looks smooth in a photograph. The surgeon may assess elasticity, laxity, stretch, previous pregnancy or major weight change, lower-pole length and whether the nipple is already low relative to the fold. A tight envelope may resist a large sudden increase and create tension. A loose envelope may accommodate volume initially but provide less long-term support. Neither situation makes a particular implant automatically correct.
This is where a request for “more volume” may actually be a request for a different contour or a lift. An implant can add volume, but it cannot reliably reposition a low nipple or remove excess skin. In selected patients, a lift, staged surgery, a different width–projection balance or a smaller device may be more coherent options. The decision belongs to the examining surgeon and patient; an online article cannot decide suitability.
The evidence is strongest for the principle of matching implant and envelope, not for a particular millimetre cutoff. The original TEPID report and other clinical series associate failure to reconcile patient wishes with tissue characteristics with problems such as thinning, ptosis, visibility, palpability, rippling, bottoming and lateral displacement. Those reports are important warnings, but they are not randomised evidence that a given volume causes a named complication in every patient.
5. Posture and body mechanics add a functional layer
Posture belongs in the consultation, but it must be handled carefully. Breast augmentation is not a treatment for back pain or spinal alignment, and no implant size should be prescribed from a posture photograph. The relevant question is whether added breast mass, projection or movement interacts with the patient’s activities and expectations.
In a 2015 study, 40 healthy volunteers wore simulated 300 g, 400 g and 800 g implants per breast inside a sports bra for six and a half hours on separate days. The researchers observed reversible changes in cervical and lumbar curves and balance with the heavier loads. This design tested temporary external loading, not healed surgical results, and its reported “threshold” should not be treated as a universal safety limit.
A 2012 study followed 48 augmentation patients with posture measurements before surgery and at one, four and twelve months. It reported an early backward repositioning of the upper body and later biomechanical adaptation. The authors also suggested that psychological and body-image factors could influence posture, meaning that the observed change could not be reduced to implant weight. These studies provide context, not a sizing equation.
Still, a patient’s real life matters. An endurance athlete, manual worker, musician, person with shoulder symptoms or someone who strongly prioritises lightness may value a different trade-off from a patient whose main goal is a substantial visual change. Those goals should be stated before the discussion narrows to cc, profile or shape.
6. Patient goals determine which trade-off is acceptable
Anatomy constrains the possible plan, but it does not define the patient’s preferred result. “Natural” can mean a gradual upper-pole slope, soft movement, limited projection, a discreet change or simply a result that looks proportionate in clothing. Another patient may prioritise upper-pole fullness, cleavage, a stronger side profile or a clear increase in volume. These are not interchangeable endpoints.
The 2016 Natrelle 410 Delphi study is device-specific and manufacturer-sponsored, so it cannot be generalised to every implant. It is nevertheless useful because the participating surgeons rated patient-desired outcome as the most essential element in implant selection and rated skin-envelope quality and breast height and width as important for implant-volume selection. Consensus is lower-level evidence than comparative trials, but it shows how goals and measurements can be considered together.
Newer patient-centred evidence points in the same direction. A 2025 retrospective analysis of 1,840 primary augmentations from one centre examined a process that involved patients in the final implant-volume decision. Eighteen patients underwent exchange because of dissatisfaction with size, a rate of 0.98% in that cohort. The study does not prove that involvement prevents revision: it was retrospective, single-centre, used one selection process and included follow-up limitations. It does support a more modest claim—that a clear, shared final decision can help align the chosen volume with the patient’s expectations.
This is consistent with NICE shared decision-making guidance: decisions should combine the best available evidence, clinical expertise and the person’s values and preferences, including the option of doing nothing. Sizers, photographs and 3D simulations can make the conversation more concrete. They cannot guarantee the healed breast because they cannot fully model pocket dissection, swelling, scar formation, muscle contraction, tissue attenuation or future change. The related review of 3D imaging, sizers and shared decision-making evidence discusses that distinction in detail.
How the variables interact in practice
Imagine two patients considering an implant with the same nominal volume. The first has a broad base, thicker tissue and a preference for a wider, less projected contour. The second has a narrower base, thinner coverage and a preference for visible forward fullness. The same cc cannot be expected to create the same shape in both patients. A device with a greater width-to-projection balance may suit one goal, while another device with a narrower footprint and more projection may be considered for the other, subject to examination and the surgeon’s judgement.
This is also why a high-profile label does not mean “larger” in a universal sense. Within a specific product family it may provide more forward projection from a narrower base, while a lower profile spreads volume more broadly. Actual millimetre dimensions, not the marketing label, should be reviewed. For plain-language context, the site’s guides to breast implant dimensions, profile and projection and body proportions explain these terms without replacing clinical assessment.
The FDA’s approved-implant labeling page also matters because device labeling and post-approval information can be updated. The exact device name, filler, surface, shape, volume, width, projection and—where relevant—height should be recorded in the consent and patient materials. The FDA has separately recommended patient labeling that supports informed decisions about benefits, risks and uncertainties. The label is not a substitute for the surgeon’s examination, but it is better evidence than an unlabeled social-media photograph.
What objective studies can and cannot predict
Three-dimensional measurement has made it possible to compare a device’s dimensions with the breast that appears after surgery. Tepper and colleagues studied 14 augmentation patients with preoperative and postoperative 3D photographs. Breast volume changed in correlation with implant size, but measured anterior–posterior projection was 20.9% less than expected from the implant dimensions, possibly because tissue in front of the implant attenuated the visible projection. The sample was small, the access route was periareolar and follow-up averaged about 143 days, so the percentage is not a personal prediction.
Ji and colleagues followed 13 dual-plane anatomical-implant patients with 3D scans at four postoperative time points. They reported that breast-volume changes were not significantly different from the later time point after three months, while several contour and landmark measures were relatively stable after six months in that cohort. This shows why early swelling and tissue adaptation should not be mistaken for the final relationship between implant geometry and breast form. It does not establish a universal settling timetable.
The 2020 anthropometric study and the larger measurement review point to the same interpretation: predictable patterns exist at group level, but individual morphology still varies. Measuring is valuable because it makes assumptions visible. It does not turn a living, changing envelope into a fixed engineering container.
A practical evidence-based consultation sequence
- Define the goal. Record the desired direction of change, what the patient wants to avoid, activity priorities and willingness to accept scars, muscle-related movement, visible or palpable edges, future revision and possible residual asymmetry.
- Examine the frame and breast base. Assess chest-wall contour, breast width and height, fold position, nipple position, spacing, asymmetry and lower-pole shape.
- Assess the envelope. Consider skin quality, stretch, existing breast tissue and coverage at the upper, lower, medial and lateral poles. Note whether excess skin or ptosis changes the question from augmentation alone to a lift or staged plan.
- Compare device dimensions. Review exact width, projection, height where relevant, shape, filler and volume. Reject the idea that cc alone is the plan.
- Discuss pocket and tissue interaction. Explain why the proposed plane may alter coverage, movement, palpability, recovery and future revision considerations, while acknowledging uncertainty in comparative studies.
- Use sizers or imaging as communication aids. Compare a small range of feasible options and state what the visualisation cannot predict. The patient should be able to repeat the intended choice and its trade-offs in their own words.
- Document the final decision. The record should contain the patient’s goals, the exact proposed device, reasonable alternatives, important risks, and the possibility that anatomy may require a different plan at the in-person examination.
For procedural context, see the site’s breast augmentation operation guide. If a patient has already reached the stage of discussing coordinated travel logistics, the breast augmentation all-inclusive package page is a separate practical resource; it is not evidence and does not replace surgical consent or device-specific labeling.
Limitations and conclusion
The anatomy-based breast implant planning evidence is persuasive as a direction but incomplete as a formula. Much of the literature consists of expert frameworks, retrospective or single-surgeon series, device-specific consensus, small 3D cohorts and studies with inconsistent definitions of width, projection, coverage and outcome. Posture studies use temporary simulated loads or small clinical cohorts. Patient-involvement findings are observational. Comparative pocket evidence remains vulnerable to bias. These limitations mean that no online calculator, photograph, sizer, 3D image or cup-size request can guarantee the final result.
The most defensible framework is proportional and shared: begin with chest width and breast base, assess skin quality and tissue coverage, consider posture and activities, then reconcile implant width, projection, shape and volume with the patient’s priorities. Volume still matters. It is simply one coordinate in a three-dimensional and values-sensitive decision. Personalised planning is not the promise of perfect symmetry or a complication-free outcome. It is a method for making the reasoning visible, reducing avoidable mismatch and helping a patient decide with realistic expectations.
Frequently asked questions
Why is anatomy more important than implant volume?
Anatomy determines how an implant’s volume is distributed and supported. Chest width, breast base, tissue coverage, skin quality, pocket and patient goals influence the visible result and the trade-offs. Volume remains important, but it cannot describe the whole plan.
What measurements are used for anatomy-based implant planning?
A surgeon may assess breast-base width and height, chest-wall contour, fold position, nipple-to-fold distance, nipple position, skin stretch and soft-tissue thickness. The exact measurements and method vary, and no set of numbers guarantees an outcome.
Does chest width affect breast implant selection?
Yes. Chest width and breast-base width help determine whether a device’s footprint and projection are proportionate to the frame. They should be interpreted with tissue coverage, skin quality, existing breast volume and the patient’s preferred silhouette.
Can a large implant correct loose skin or a low nipple?
An implant adds volume but does not reliably remove excess skin or reposition a low nipple. Some patients may need a lift, a different volume–projection balance, staged treatment or acceptance of a residual difference. Suitability can only be assessed clinically.
Does posture determine the right implant size?
No. Posture is one functional consideration, not a sizing formula. Small studies suggest that temporary or added breast mass can interact with posture and balance, but they do not define a universal implant-weight limit or prove that augmentation improves spinal symptoms.
Are sizers and 3D simulations accurate enough to choose an implant?
They can help compare feasible options and communicate preferences, but they are approximations. They cannot fully predict dissection, swelling, scar formation, muscle contraction, tissue attenuation, ageing or the healed breast.
Can anatomy-based planning guarantee no implant complications?
No. It may help identify a mismatch and inform pocket and coverage decisions, but complications such as asymmetry, rippling, malposition, capsular contracture, rupture and later tissue change can still occur.
Visible sources and references
- Perry D, Frame JD. The history and development of breast implants. Annals of The Royal College of Surgeons of England. 2020;102:478–482. Historical and surgical context for chest-wall symmetry, frame, breast position, envelope compliance and the means of adding volume.
- Tebbetts JB. A system for breast implant selection based on patient tissue characteristics and implant-soft tissue dynamics. Plastic and Reconstructive Surgery. 2002;109:1396–1409. PMID 11964998; DOI 10.1097/00006534-200204010-00030. Tissue-based framework using base width, skin stretch, fold distance and pinch thickness.
- Tebbetts JB, Adams WP. Five critical decisions in breast augmentation using five measurements in 5 minutes. Plastic and Reconstructive Surgery. 2005;116:2005–2016. PMID 16327616. A case-series decision-support process, not randomised evidence.
- Adams WP Jr, McKee D. Matching the Implant to the Breast. Plastic and Reconstructive Surgery. 2016;138:987–994. PMID 27782989; DOI 10.1097/PRS.0000000000002623. Systematic review of 33 implant-selection systems.
- Tepper OM, et al. 3D analysis of breast augmentation defines operative changes and their relationship to implant dimensions. Annals of Plastic Surgery. 2009;62:570–575. PMID 19387164; DOI 10.1097/SAP.0b013e31819faff9. Small objective 3D cohort.
- Ji K, et al. A prospective study of breast dynamic morphological changes after dual-plane augmentation mammaplasty with 3D scanning. PLOS ONE. 2014;9:e93010. PMID 24671190; DOI 10.1371/journal.pone.0093010. Prospective 3D follow-up of 13 patients.
- Charles-de-Sá L, et al. Anthropometric aspects in the breast augmentation. Aesthetic Plastic Surgery. 2020;44:1498–1507. PMID 32728763; DOI 10.1007/s00266-020-01853-5. Prospective study of 74 candidates grouped by implant volume; journal evidence level IV.
- Bolletta E, McGoldrick C, Hall-Findlay EJ. Aesthetic breast surgery: What do the measurements reveal?. Aesthetic Surgery Journal. 2020;40:742–752. PMID 31541247; DOI 10.1093/asj/sjz249. Measurement review using one-surgeon, one-year follow-up data.
- Yuan M, et al. Outcomes in subfascial versus subglandular planes in breast augmentation. Aesthetic Surgery Journal. 2024;44:NP639–NP644. PMID 38825810; DOI 10.1093/asj/sjae118. Systematic review/meta-analysis with high risk of bias in included studies.
- Brown T, Brown S, Murphy T. Breast durometer (Mammometer). Aesthetic Plastic Surgery. 2017;41:265–274. PMID 28130561; DOI 10.1007/s00266-017-0783-5. Level-III study of objective firmness measurement.
- Nicoletti G, et al. Objective clinical assessment of posture patterns after implant breast augmentation. Plastic and Reconstructive Surgery. 2015;136:162e–170e. PMID 26218390; DOI 10.1097/PRS.0000000000001454. Temporary simulated-load study in 40 healthy volunteers.
- Mazzocchi M, et al. A study of postural changes after breast augmentation. Aesthetic Plastic Surgery. 2012;36:570–577. PMID 22083412; DOI 10.1007/s00266-011-9841-6. Prospective posture follow-up in 48 patients.
- Heden P, et al. Delphi study consensus recommendations for Natrelle 410. Plastic and Reconstructive Surgery Global Open. 2016. Device-specific, manufacturer-sponsored expert consensus; not a universal sizing rule.
- Kolasiński J, et al. The effect of patient involvement in implant size selection. Aesthetic Surgery Journal. 2025;45:899–905. PMID 40378273; DOI 10.1093/asj/sjaf085. Retrospective single-centre analysis of 1,840 primary augmentations.
- NICE guideline NG197: Shared decision making. Guidance on combining evidence, clinical expertise, patient values and preferences, including the option of no treatment.
- U.S. FDA: Labeling for approved breast implants. Current regulator index for patient labeling, physician labeling and post-approval updates.
Author and medical review
Author: BreastAugmentationInTurkey.org Editorial Team
Medical reviewer: Qualified plastic surgeon — to be confirmed before publication
Published / evidence updated: 11 September 2026
Editorial scope: Primary cosmetic augmentation evidence is prioritised. Reconstruction, revision, congenital chest differences and significant ptosis are identified as populations that may require different planning. No prices, package comparisons, hotel details, transfers or travel schedules are included in this evidence article.